Callan Family Office LLC Sells 1,831 Shares of Danaher Corporation (NYSE:DHR)

Key Points

• Callan Family Office LLC reduced its stake in Danaher Corporation by 16.4%, owning 9,316 shares worth approximately $1.91 million after selling 1,831 shares in the first quarter.
• Danaher reported a quarterly earnings per share (EPS) of $1.80, surpassing estimates by $0.16, with a net revenue of $5.94 billion.
• Analysts have given Danaher a rating of "Moderate Buy" with an average price target of $247.61, while several firms have adjusted their price objectives for the stock in recent weeks.

Callan Family Office LLC cut its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 16.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,316 shares of the conglomerate's stock after selling 1,831 shares during the quarter. Callan Family Office LLC's holdings in Danaher were worth $1,910,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Ballast Inc. boosted its stake in Danaher by 1.8% during the first quarter. Ballast Inc. now owns 5,343 shares of the conglomerate's stock worth $1,095,000 after acquiring an additional 93 shares in the last quarter. Independent Advisor Alliance boosted its stake in Danaher by 2.1% during the first quarter. Independent Advisor Alliance now owns 5,392 shares of the conglomerate's stock worth $1,105,000 after acquiring an additional 110 shares in the last quarter. Cove Private Wealth LLC boosted its stake in Danaher by 41.8% during the first quarter. Cove Private Wealth LLC now owns 2,836 shares of the conglomerate's stock worth $581,000 after acquiring an additional 836 shares in the last quarter. SouthState Corp boosted its stake in Danaher by 0.9% during the first quarter. SouthState Corp now owns 100,952 shares of the conglomerate's stock worth $20,695,000 after acquiring an additional 856 shares in the last quarter. Finally, Cobblestone Capital Advisors LLC NY boosted its stake in Danaher by 102.0% during the first quarter. Cobblestone Capital Advisors LLC NY now owns 2,056 shares of the conglomerate's stock worth $421,000 after acquiring an additional 1,038 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of DHR traded up $0.62 during trading hours on Friday, hitting $210.84. The company's stock had a trading volume of 3,210,213 shares, compared to its average volume of 4,658,279. The business has a 50 day simple moving average of $199.94 and a two-hundred day simple moving average of $199.87. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a market cap of $150.97 billion, a price-to-earnings ratio of 44.86, a PEG ratio of 2.93 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the business earned $1.72 earnings per share. Danaher's revenue was up 3.4% compared to the same quarter last year. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent research reports. UBS Group dropped their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Guggenheim reaffirmed a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. The Goldman Sachs Group dropped their price objective on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research note on Friday, July 11th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.